HK1112399A1 - 穩定抗痴呆藥物的方法 - Google Patents

穩定抗痴呆藥物的方法

Info

Publication number
HK1112399A1
HK1112399A1 HK08101338.1A HK08101338A HK1112399A1 HK 1112399 A1 HK1112399 A1 HK 1112399A1 HK 08101338 A HK08101338 A HK 08101338A HK 1112399 A1 HK1112399 A1 HK 1112399A1
Authority
HK
Hong Kong
Prior art keywords
dementia drug
stabilizing anti
stabilizing
dementia
drug
Prior art date
Application number
HK08101338.1A
Other languages
English (en)
Inventor
Yosuke Ueki
Yasuyuki Suzuki
Satoshi Fujioka
Original Assignee
衛材研發管理株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36615033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1112399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 衛材研發管理株式會社 filed Critical 衛材研發管理株式會社
Publication of HK1112399A1 publication Critical patent/HK1112399A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08101338.1A 2004-12-27 2008-02-05 穩定抗痴呆藥物的方法 HK1112399A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004376770 2004-12-27
JP2005041492 2005-02-18
PCT/JP2005/024254 WO2006070930A1 (en) 2004-12-27 2005-12-27 Method for stabilizing anti-dementia drug

Publications (1)

Publication Number Publication Date
HK1112399A1 true HK1112399A1 (zh) 2008-09-05

Family

ID=36615033

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101338.1A HK1112399A1 (zh) 2004-12-27 2008-02-05 穩定抗痴呆藥物的方法

Country Status (14)

Country Link
US (2) US8481565B2 (zh)
EP (1) EP1830886B1 (zh)
JP (2) JP2008525313A (zh)
KR (1) KR100866720B1 (zh)
AU (1) AU2005320547B2 (zh)
BR (1) BRPI0518396A2 (zh)
CA (1) CA2592605C (zh)
HK (1) HK1112399A1 (zh)
IL (1) IL183650A (zh)
MX (1) MX2007007836A (zh)
NO (1) NO20073482L (zh)
NZ (1) NZ555693A (zh)
RU (1) RU2401125C2 (zh)
WO (1) WO2006070930A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
US20080131490A1 (en) * 2006-12-01 2008-06-05 Akinori Hanatani Stabilized donepezil-containing patch preparation
CA2670995A1 (en) * 2006-12-01 2008-06-05 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
WO2008066179A1 (fr) * 2006-12-01 2008-06-05 Nitto Denko Corporation Préparation d'absorption percutanée
TW200838569A (en) * 2006-12-01 2008-10-01 Nitto Denko Corp Stabilized donepezil-containing patch preparation
US20100016362A1 (en) * 2007-01-19 2010-01-21 Eisai R & D Management Co., Ltd. Stabilized pharmaceutical composition containing donepezil, process of producing same and method for stabilization
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
MX2010010460A (es) 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
KR101674240B1 (ko) * 2009-12-22 2016-11-08 아시노 아게 리바스티그민 또는 그의 유도체 투여용 경피 치료 시스템
JP5933268B2 (ja) * 2009-12-28 2016-06-08 ニプロ株式会社 品質が向上した経口剤
US20110218216A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP2011213606A (ja) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd ドネペジルを含有する固形製剤の製造方法
WO2012101653A2 (en) * 2011-01-25 2012-08-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
CN103417490B (zh) * 2012-05-21 2015-06-17 成都康弘药业集团股份有限公司 一种含有盐酸多奈哌齐的颗粒剂及其制备方法
KR102241113B1 (ko) 2013-02-28 2021-04-15 루핀 리미티드 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물
EP2961392B1 (en) 2013-02-28 2020-10-28 Lupin Limited Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
KR101938872B1 (ko) 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US10603292B2 (en) 2017-05-31 2020-03-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102218593B1 (ko) * 2020-05-13 2021-02-22 동아에스티 주식회사 안정성이 향상된 도네페질 함유 경피 흡수제제

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1894239A (en) * 1930-01-20 1933-01-10 Ig Farbenindustrie Ag Production of molybdenum and tungsten carbonyls
US2327996A (en) 1941-11-24 1943-08-31 Thompson W Burnam Process of dehydrating mineral oil emulsions
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
SE452177B (sv) 1983-09-30 1987-11-16 Nils Anders Lennart Wikdahl Anordning for fraktionering av fibersuspensioner
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
NL8500724A (nl) 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IL81419A0 (en) 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NL8701335A (nl) * 1986-06-21 1988-01-18 Sandoz Ag Orale farmaceutische preparaten.
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
CA1308357C (en) * 1987-01-28 1992-10-06 Tohru Chiba Method for the preparation of a coated solid medicament
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US5254347A (en) 1988-03-31 1993-10-19 Tanabe Seiyaku Co., Ltd. Controlled release pharmaceutical preparation and method for producing the same
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3818207A1 (de) 1988-05-28 1989-11-30 Bosch Gmbh Robert Reifendruck- und temperatursensor
DE3827214A1 (de) * 1988-08-11 1990-02-15 Roehm Gmbh Retardierte arzneiform und verfahren zu ihrer herstellung
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
NZ231281A (en) 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5278474A (en) * 1989-01-12 1994-01-11 Tokyo Densoku Kabushiki Kaisha Discharge tube
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
IT1258143B (it) 1992-09-11 1996-02-20 Alfa Wassermann Spa Compresse a cessione programmata contenenti naproxen
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
ATE278687T1 (de) 1993-12-29 2004-10-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als therapeutische mittel
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
FI98343C (fi) 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6310085B1 (en) 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
DE19707655A1 (de) 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AU7550398A (en) * 1997-06-05 1998-12-21 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use
TW446561B (en) * 1997-06-30 2001-07-21 Dev Center Biotechnology Improved stabilization of prostaglandin drug
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
JP3797764B2 (ja) 1997-10-01 2006-07-19 エーザイ株式会社 光安定化組成物
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US20030092737A1 (en) * 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
JP3987655B2 (ja) 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
EP1025858A4 (en) * 1998-08-28 2009-03-11 Eisai R&D Man Co Ltd DRUGS WITH REDUCED BITTERNESS ETC.
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
WO2000024423A1 (fr) * 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Particules a liberation prolongee
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
HUP0104778A3 (en) * 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
US6659463B2 (en) 1999-01-08 2003-12-09 Thomas J. Mackey Interconnecting miniature toy figurine bases with record tracking system
DE19901040A1 (de) 1999-01-14 2000-07-20 Knoll Ag Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE69913138T2 (de) * 1999-03-31 2004-08-26 Eisai Co., Ltd. Stabilisierte zusammensetzung mit nootropen wirkstoffen
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
BR0007360A (pt) * 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
WO2001066096A2 (en) * 2000-03-06 2001-09-13 Immune Network Ltd. Compositions for prevention and treatment of dementia
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
IN192159B (zh) 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002024174A2 (en) 2000-09-22 2002-03-28 Galephar M/F Sustained release composition containing clarithromycin
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
AU2001278673A1 (en) 2000-10-30 2002-05-15 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
EP1385486A4 (en) 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
WO2002100382A2 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US6693769B2 (en) * 2001-06-18 2004-02-17 Hitachi Global Storage Technologies Netherlands B.V. High data rate write head
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JP3474870B2 (ja) * 2001-08-08 2003-12-08 菱計装株式会社 昇降機
JP4848101B2 (ja) 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
EA200400343A1 (ru) * 2001-08-29 2004-08-26 Рэнбакси Лабораториз Лимитед Композиция с контролируемым высвобождением кларитромицина или тинидазола
SI1446119T1 (sl) * 2001-09-18 2006-08-31 Nycomed Danmark Aps Sestavki, ki obsegajo ipratorij in ksilometazolin, za zdravljenje obicajnega prehlada
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
BR0212950A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
US20030118649A1 (en) * 2001-10-04 2003-06-26 Jinming Gao Drug delivery devices and methods
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
AUPR839001A0 (en) * 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
RU2311903C2 (ru) 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
BR0214372A (pt) 2001-11-21 2004-10-26 Eisai Co Ltd Composição de um preparado contendo um composto ácido-instavel fisiologicamente ativo e processo para a produção da mesma
US20050163846A1 (en) 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
CA2470636A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
EP1481689A4 (en) * 2002-02-07 2005-10-05 Eisai Co Ltd AGENT FOR STIMULATING HAIR GROWTH, PERCUTANEOUS PREPARATIONS AND METHOD FOR STIMULATING HAIR GROWTH
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
TWI286481B (en) * 2002-02-21 2007-09-11 Otsuka Pharma Co Ltd Sustained release preparations and process for producing the same
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
ITMI20020515A1 (it) 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
JP5105684B2 (ja) 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
FR2838647B1 (fr) 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
AU2003269741A1 (en) 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
DE10224170A1 (de) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003232398A1 (en) 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
SI21223A (sl) 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
EP1635794A2 (en) 2002-08-23 2006-03-22 Ranbaxy Laboratories, Ltd. Nitrofurantoin controlled release dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
KR100852834B1 (ko) * 2002-10-24 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
DK1556021T3 (da) 2002-10-24 2008-04-28 Immupharm As Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
AU2003299819A1 (en) * 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
CN100594899C (zh) 2003-01-24 2010-03-24 控制递送系统有限公司 经眼部递送碳酸酐酶抑制剂的持续释放系统和方法
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US7439365B2 (en) * 2003-11-17 2008-10-21 Usv, Ltd. Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2004108067A2 (en) 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
MXPA05010636A (es) 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US20040208928A1 (en) 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040208932A1 (en) 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
JP2004339162A (ja) 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
JP2006527774A (ja) 2003-06-16 2006-12-07 アラーガン、インコーポレイテッド メマンチン経口製剤
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
EP1653922A2 (en) * 2003-08-06 2006-05-10 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
US20050129751A1 (en) * 2003-12-16 2005-06-16 Rothenberg Barry E. Drug delivery compositions and methods
US20050129759A1 (en) * 2003-12-16 2005-06-16 Milan Sojka Sustained release compositions and controlled delivery method
AU2004308973A1 (en) 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US20050163843A1 (en) 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
AU2005209242A1 (en) 2004-01-26 2005-08-11 Psivida Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050181047A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US20050181044A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
US20050186275A1 (en) 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
EP1728512A1 (en) 2004-03-26 2006-12-06 Eisai R&D Management Co., Ltd. Controlled-leaching preparation and process for producing the same
US20050220875A1 (en) 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8535716B2 (en) 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006063025A1 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising donepezil
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
WO2006118265A1 (ja) 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
CN1709229A (zh) 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚口腔崩解片及其制备方法

Also Published As

Publication number Publication date
NZ555693A (en) 2010-10-29
US20080213368A1 (en) 2008-09-04
KR20070086667A (ko) 2007-08-27
CA2592605A1 (en) 2006-07-06
IL183650A (en) 2013-12-31
NO20073482L (no) 2007-09-27
JP2008525313A (ja) 2008-07-17
RU2007128767A (ru) 2009-02-10
BRPI0518396A2 (pt) 2008-11-18
WO2006070930A1 (en) 2006-07-06
US8507527B2 (en) 2013-08-13
JP5514249B2 (ja) 2014-06-04
CA2592605C (en) 2010-12-07
IL183650A0 (en) 2007-09-20
MX2007007836A (es) 2007-08-20
US8481565B2 (en) 2013-07-09
JP2012144568A (ja) 2012-08-02
KR100866720B1 (ko) 2008-11-05
EP1830886A4 (en) 2012-10-10
EP1830886B1 (en) 2016-04-13
AU2005320547A1 (en) 2006-07-06
RU2401125C2 (ru) 2010-10-10
AU2005320547B2 (en) 2009-02-05
US20100152164A1 (en) 2010-06-17
EP1830886A1 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
IL183650A0 (en) Method for stabilizing anti-dementia drug
GB0526291D0 (en) Therapeutic method
IL182614A0 (en) Pharmaceutical compounds
HK1108152A1 (en) Apparatus for pharmaceutical production
EP1799865A4 (en) PROCESS FOR THE ADMINISTRATION OF ILOPERIDONE
ZA200705118B (en) Method for stabilizing anti-dementia drug
ZA200600495B (en) Method of treatment for improved bioavailability
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
EP1782821A4 (en) MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION
PL1934388T3 (pl) Sposób projektowania leków
GB0424742D0 (en) Pharmaceutical compounds
GB0428554D0 (en) Pharmaceutical compounds
TWI315261B (en) Method for transferring-printing
GB0420828D0 (en) Therapeutic method
GB0420822D0 (en) Therapeutic method
GB0420823D0 (en) Therapeutic method
GB0521540D0 (en) Therapeutic method
GB0509930D0 (en) Therapeutic method
GB0510213D0 (en) Therapeutic method
GB0509929D0 (en) Therapeutic method
GB0521547D0 (en) Therapeutic method
GB0509932D0 (en) Therapeutic method
GB0521562D0 (en) Therapeutic method
HUP0401136A3 (en) Method for post-blinding of gas-plumbing
GB0415084D0 (en) Pharmaceutical compounds